drugset / Trial / NCT04266028
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
RandomizedSequentialDouble-blindOther
Summary
Randomized, double-blind placebo-controlled phase I study to investigate the safety and tolerability of ascending doses of DM-101 in adult subjects with birch pollen allergy.
Timeline
- Start
- 2020-02-11
- Primary completion
- 2021-05-31
- Completion
- 2021-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DM-101 | Unknown | 30 ng | Subcutaneous |
| Subject | DM-101 | Unknown | 100 ng | Subcutaneous |
| Subject | DM-101 | Unknown | 300 ng | Subcutaneous |
| Subject | DM-101 | Unknown | 25000 ng | Subcutaneous |